Inclusion Criteria:  Subjects aged ≥18 and ≤75 years old； ECOG performance status score 0-1； Stage ⅠB-ⅡA（according to the 8th Edition of the AJCC Staging system）； Complete surgical resection of the primary NSCLC is mandatory； Histologically confirmed diagnosis of high-risk pathological subtype (micropapillary, solid pattern or spread through air spaces [STAS], etc.); The tumour harbours one of the most common EGFR mutations (19del or L858R) ; Normal organ and bone marrow function measured before the study as defined below:  1) Hemoglobin (HGB)≥90g/L 2) White blood cell count (WBC) is 4.0~10×10^9/L 3) Absolute value of neutrophil (ANC)≥1.5×10^9/L 4) Platelet (PLT) count≥100×109/L 5) Serum total bilirubin (TBIL)≤1.5×ULN 6) AST and/or ALT≤2.5×ULN 7) International normalized ratio（INR）≤1.5 and activated partial thromboplastin time (APTT) is normal 8) Serum creatinine (SCr)≤1.5 × ULN 8. No previous systemic anti-tumor therapy for malignant tumor, such as chemotherapy, radiotherapy or hormonotherapy. No history of other malignancies, subjects with prostate cancer who received hormone therapy and had more than 5 years of DFS were excluded; 9. Subjects have voluntarily participated, signed and dated informed consent.  Exclusion Criteria:  Double primary lung cancer or multiple primary lung cancer; Subjects with mental illness; Presence or concomitant hemorrhagic diseases; Pregnancy or lactation; Known or suspected to be allergic to Furmonertinib and / or other components of their preparations.